PDF(Pubmed)
Abstract：
Human papilloma virus (HPV) infection and its progression still represent a great medical challenge worldwide. Clinical evidence has demonstrated the beneficial effects of polyhexamethylene biguanide (PHMB) on HPV clinical manifestations; however, evidence of the effect of this molecule on HPV viral load is still lacking. In this in vitro study, 13 ThinPrep Papanicolaou (Pap) tests were treated with a PHMB solution (0.10 g/100 mL) for 2 h. We observed no cytological changes but a significant reduction in the viral load of high-risk (HR) HPV after PHMB treatment, also revealing a dose-dependent antiviral effect. In addition, by stratifying the obtained results according to HR-HPV genotype, we observed a significant reduction in the viral load of HPV 16, P2 (56, 59, 66), 31, and P3 (35, 39, 68) and a strong decrease in the viral load of HPV 45, 52, and P1 (33, 58). Overall, 85% of the analyzed cervical cell samples exhibited an improvement in HPV viral load after PHMB exposure, while only 15% remain unchanged. For the first time, the data from this pilot study support the activity of PHMB on a specific phase of the HPV viral lifecycle, the one regarding the newly generated virions, reducing viral load and thus blocking the infection of other cervical cells.
摘要：
人乳头瘤病毒（HPV）感染及其进展仍然是全球范围内巨大的医学挑战。临床证据表明聚六亚甲基双胍（PHMB）对HPV临床表现的有益作用；然而，目前尚缺乏该分子对HPV病毒载量影响的证据.在这项体外研究中，13ThinPrepPapanicolaou（Pap）测试用PHMB溶液（0.10g/100mL）处理2小时。我们没有观察到细胞学变化，但PHMB治疗后高风险（HR）HPV的病毒载量显着降低，也揭示了剂量依赖性的抗病毒作用。此外,通过根据HR-HPV基因型对获得的结果进行分层，我们观察到HPV16，P2（56，59，66）的病毒载量显着降低，31，和P3（35，39，68）和HPV45，52和P1（33，58）的病毒载量的强烈降低。总的来说,在PHMB暴露后，85%的宫颈细胞样本显示HPV病毒载量改善，只有15%保持不变。第一次,这项试点研究的数据支持PHMB在HPV病毒生命周期的特定阶段的活性，关于新产生的病毒体，减少病毒载量，从而阻断其他宫颈细胞的感染。
